Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event

Next Previous
X
Search
Trial Profile

Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sibutramine (Primary)
  • Indications Cardiovascular disorders; Obesity; Overweight
  • Focus Registrational; Therapeutic Use
  • Acronyms SCOUT
  • Sponsors Abbott Laboratories

    • Most Recent Events

    • 04 Sep 2020 Results assessing lifestyle intervention with or without the aid of pharmacological treatment in women over the age of 55, presented at the 2020 European and International Congress on Obesity.
    • 12 May 2012 Results presented at the 19th European Congress on Obesity.
    • 08 Oct 2010 Based primarily on the results of this trial, Abbott will voluntarily withdraw sibutramine from the Canadian market.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top